Javlor

Vinflunine, the active ingredient in Javlor, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is indicated for patients with advanced or metastatic urothelial carcinoma who have progressed after platinum‑based chemotherapy.

GNH USA supplies Javlor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Javlor is a Vinca alkaloid used in the treatment of urothelial carcinoma, a cancer of the bladder and urinary tract. - Advanced urothelial carcinoma: provides disease control after platinum‑based chemotherapy failure. - Metastatic urothelial carcinoma: offers a therapeutic option for patients with cancer spread beyond the bladder. - Urothelial carcinoma (post‑platinum): used to extend survival in patients whose disease has progressed following standard platinum regimens.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Nausea and vomiting: gastrointestinal upset. - Constipation: decreased bowel movements. - Fatigue: general weakness and tiredness. - Alopecia: hair loss.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection. - Hemorrhage: bleeding complications. - Cardiac toxicity: arrhythmias or reduced cardiac function. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Renal failure: impaired kidney function. - Thromboembolic events: blood clots in veins or arteries.

Before initiating Vinflunine therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Blood count monitoring: perform regular CBC to detect myelosuppression. - Renal function assessment: evaluate creatinine clearance prior to each cycle. - Hepatic function assessment: check liver enzymes for potential toxicity. - Infection vigilance: avoid use in patients with active severe infections. - Cardiac caution: monitor ECG in patients with known heart disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concurrent Vinca alkaloids or taxanes: additive neurotoxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinflunine exposure. - Potent CYP3A4 inducers (e.g., rifampicin): reduce therapeutic levels. - Nephrotoxic agents (e.g., cisplatin): heightened renal risk. - Anticoagulants (e.g., warfarin): increased bleeding tendency.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may raise plasma concentrations. - Other myelosuppressive drugs (e.g., cyclophosphamide): enhanced bone‑marrow suppression. - CYP2C9 or CYP2C19 inhibitors: potential modest increase in exposure. - Diuretics: may affect renal clearance. - Proton‑pump inhibitors: possible alteration of absorption dynamics.